Literature DB >> 31392906

Decision points for individualized hormonal stimulation with recombinant gonadotropins for treatment of women with infertility.

Bruno Lunenfeld1, Wilma Bilger2, Salvatore Longobardi3, Jan Kirsten4, Thomas D'Hooghe3,5,6, Sesh K Sunkara7.   

Abstract

It is essential that fertility treatment is individualized based on a thorough diagnostic work-up, with treatment tailored to the patients' requirements. This individualization should be kept in mind during the main decision points that occur before and during treatment. Treatment customization must include consideration of both the woman and her partner involved in the process together, including their collective treatment goals. Once treatment goals have been agreed and diagnostic evaluations performed, personalization based on patient characteristics, together with an understanding of treatment goals and patient preferences, enables the selection of appropriate treatments, protocols, products and their dosing. Following treatment initiation, monitoring and adaptation of product and dose can then ensure optimal outcomes. Currently, it is not possible to base treatment decisions on every characteristic of the patient and personalization is based on biomarkers that have been identified as the most relevant. However, in the future, the use of artificial intelligence coupled with continuous monitoring should enable greater individualization and improve outcomes. This review considers the current state-of-the-art related to decision points during individualized treatment of female infertility, before looking at future developments that might further assist in making individualized treatment decisions, including the use of computer-assisted decision making.

Entities:  

Keywords:  ART; Gonadotropin; decision points; personalized medicine; treatment algorithm

Mesh:

Substances:

Year:  2019        PMID: 31392906     DOI: 10.1080/09513590.2019.1650345

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

Review 1.  Dose adjustment of follicle-stimulating hormone (FSH) during ovarian stimulation as part of medically-assisted reproduction in clinical studies: a systematic review covering 10 years (2007-2017).

Authors:  Human Fatemi; Wilma Bilger; Deborah Denis; Georg Griesinger; Antonio La Marca; Salvatore Longobardi; Mary Mahony; Xiaoyan Yin; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-05-11       Impact factor: 5.211

2.  A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study.

Authors:  Bum Chae Choi; Canquan Zhou; Hong Ye; Yun Sun; Ying Zhong; Fei Gong; Ivan Sini; Nadezda Abramova; Salvatore Longobardi; Miranda Hickey; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2022-01-17       Impact factor: 5.211

3.  Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.

Authors:  Klaus F Bühler; Robert Fischer; Patrice Verpillat; Arthur Allignol; Sandra Guedes; Emmanuelle Boutmy; Wilma Bilger; Emilia Richter; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-06-16       Impact factor: 5.211

4.  Management Strategies for POSEIDON Group 2.

Authors:  Sesh Kamal Sunkara; G A Ramaraju; Mohan Shashikant Kamath
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-27       Impact factor: 5.555

5.  The Frequency of Ovarian Hyperstimulation Syndrome and Thromboembolism with Originator Recombinant Human Follitropin Alfa (GONAL-f) for Medically Assisted Reproduction: A Systematic Review.

Authors:  Erica Velthuis; Julie Hubbard; Salvatore Longobardi; Thomas D'Hooghe
Journal:  Adv Ther       Date:  2020-10-15       Impact factor: 3.845

6.  Recombinant Human Follicle-Stimulating Hormone Alfa Dose Adjustment in US Clinical Practice: An Observational, Retrospective Analysis of a Real-World Electronic Medical Records Database.

Authors:  Mary C Mahony; Brooke Hayward; Gilbert L Mottla; Kevin S Richter; Stephanie Beall; G David Ball; Thomas D'Hooghe
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.